Deep Learning in Drug Discovery and Medicine; Scratching the Surface
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The practice of medicine is ever evolving. Diagnosing disease, which is often the first step in a cure, has seen a sea change from the discerning hands of the neighborhood physician to the use of sophisticated machines to use of information gleaned from biomarkers obtained by the most minimally invasive of means. The last 100 or so years have borne witness to the enormous success story of allopathy, a practice that found favor over earlier practices of medical purgatory and homeopathy. Nevertheless, failures of this approach coupled with the omics and bioinformatics revolution spurred precision medicine, a platform wherein the molecular profile of an individual patient drives the selection of therapy. Indeed, precision medicine-based therapies that first found their place in oncology are rapidly finding uses in autoimmune, renal and other diseases. More recently a new renaissance that is shaping everyday life is making its way into healthcare. Drug discovery and medicine that started with Ayurveda in India are now benefiting from an altogether different artificial intelligence (AI)—one which is automating the invention of new chemical entities and the mining of large databases in health-privacy-protected vaults. Indeed, disciplines as diverse as language, neurophysiology, chemistry, toxicology, biostatistics, medicine and computing have come together to harness algorithms based on transfer learning and recurrent neural networks to design novel drug candidates, a priori inform on their safety, metabolism and clearance, and engineer their delivery but only on demand, all the while cataloging and comparing omics signatures across traditionally classified diseases to enable basket treatment strategies. This review highlights inroads made and being made in directed-drug design and molecular therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Mindfulness training as a clinical intervention: a conceptual and empirical review
Baer, R. A. (2003) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.bpg015 · Cited by 4,577
Mindfulness training as a clinical intervention: A conceptual and empirical review.
Baer, R. A. (2003) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy/bpg015 · Cited by 4,576
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning
Alipanahi, B., Delong, A., Weirauch, M. T., & Frey, B. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3300 · Cited by 2,873
ChIP–seq: advantages and challenges of a maturing technology
Park, P. J. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2641 · Cited by 2,217 · cited 1×
“ChIP-seq, a technology that couples chromatin immunoprecipitation with massively parallel sequencing, is capable of mapping genome-wide TFBSs [38,39].”
BackgroundThe rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537 · cited 1×
“Another method to facilitate the synthetic process of novel drug candidates involves a continuous loop of self-learning in which, initially, it takes advantage of an existing data set of known bioactive compounds and is expected to produce therapeutically relevant structures [65].”
MethodRobertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., et al. (2007) · Nature Methods · doi:10.1038/nmeth1068 · Cited by 1,454 · cited 1×
“ChIP-seq, a technology that couples chromatin immunoprecipitation with massively parallel sequencing, is capable of mapping genome-wide TFBSs [38,39].”
BackgroundFDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 1×
“HDAC inhibitors show efficacy in treatment of T cell lymphoma [25].”
BackgroundDeep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723
Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data
Valouev, A., Johnson, D. S., Sundquist, A., Medina, C., Anton, E., Batzoglou, S., Myers, R. M., & Sidow, A. (2008) · Nature Methods · doi:10.1038/nmeth.1246 · Cited by 695 · cited 1×
“Some of the popular models are MACS [40], ODIN [41], Hpeak [42], QuEST [43], MOSAiCS [44] and many others.”
MethodApplication of Generative Autoencoder in De Novo Molecular Design
Blaschke, T., Olivecrona, M., Engkvist, O., Bajorath, J., & Chen, H. (2018) · Molecular Informatics · doi:10.1002/minf.201700123 · Cited by 411
Precision oncology: an overview
Garraway, L. A., Verweij, J., & Ballman, K. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4799 · Cited by 405
De Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373 · cited 1×
“[63] have demonstrated the applicability of AI in delivering novel synthetically feasible bioactive compounds for the first time.”
BackgroundEpigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239 · cited 1×
“Diabetic retinopathy is known to be associated with a number of epigenetic markers, including methylation of the superoxide dismutase 2 (Sod2) and matrix metalloproteinase-9 (MMP-9) genes, an increase in transcription of Lysine-specific histone demethylase 1 (LSD1), a H3K4 and H3K9 demethylase, and various DNA Methyl-…”
Background
Cited by
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
A Review of the Role of Artificial Intelligence in Healthcare
Al Kuwaiti, A., Nazer, K., Al-Reedy, A., Al-Shehri, S., Al-Muhanna, A., Subbarayalu, A. V., Al Muhanna, D., & Al-Muhanna, F. A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060951 · Cited by 915
Machine Learning Methods in Drug Discovery
Patel, L., Shukla, T., Huang, X., Ussery, D. W., & Wang, S. (2020) · Molecules · doi:10.3390/molecules25225277 · Cited by 460
Artificial Intelligence for Drug Toxicity and Safety
Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.005 · Cited by 363
Visan, A. I., & Negut, I. (2024) · Life · doi:10.3390/life14020233 · Cited by 279
Metadata
- Authors
- Dana, D., Gadhiya, S., St. Surin, L., Li, D., Naaz, F., Ali, Q., Paka, L., Yamin, M., Narayan, M., Goldberg, I., & Narayan, P.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-09-18
- Volume
- 23
- Issue
- 9
- Pages
- 2384
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2890626570
- Cited by
- 142
- References
- 16
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.